Clinical use of circulating tumor cells in urothelial carcinoma: current situation and future
-
摘要: 尿路上皮癌(urothelial carcinoma，UC)是泌尿系统中最常见的恶性肿瘤之一，其中膀胱尿路上皮癌(bladder urothelial carcinoma，BLCA)占多数。由于UC的高复发率，患者需要定期复查，但传统的UC诊断和监测方法如尿液细胞学和影像学检查等存在灵敏度特异度低、费用昂贵等问题，因此，迫切需要一种新型、无创、低成本且准确度高的诊断方法改善现状。循环肿瘤细胞(circulating tumor cells，CTCs)作为无创性的癌症检测工具，近年来备受瞩目，特别是在癌症管理中的潜在应用。本文对CTCs在UC中早期诊断、疗效监测和预后评估等方面进行系统综述，为UC的诊断和治疗带来新的可能性。Abstract: Urothelial carcinoma (UC) is one of the most common malignant tumors in the urinary system, of which urothelial carcinoma of bladder is the majority. Due to the high recurrence rate of UC, patients need to be reviewed regularly. However, traditional methods of diagnosis and monitoring of UC, such as urine cytology and imaging, have some problems such as low sensitivity and specificity and high cost. Therefore, a new, non-invasive, low-cost and high accuracy diagnostic method is urgently needed to improve the current situation. Circulating tumor cells (CTCs) have attracted much attention in recent years as non-invasive cancer detection tools, especially for their potential applications in cancer management. In this paper, the early diagnosis, efficacy monitoring and prognosis evaluation of CTCs in UC are systematically reviewed, which brings new possibilities for the diagnosis and treatment of UC.
-
Key words:
- circulating tumor cells /
- urothelial carcinoma /
- early diagnosis /
- efficacy monitoring /
- prognosis
-
-
[1] Wu SY, Li R, Jiang YH, et al. Liquid biopsy in urothelial carcinoma: detection techniques and clinical applications[J]. Biomed Pharmacother, 2023, 165: 115027. doi: 10.1016/j.biopha.2023.115027
[2] Siegel RL, Miller KD, Hannah E. Fuchs. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[4] Wu JL, Lin YD, Yang KW, et al. Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial[J]. Mol Cancer, 2024, 23(1): 57. doi: 10.1186/s12943-024-01974-4
[5] 孙之冰, 徐维章. 尿液循环肿瘤DNA在膀胱癌早期诊断及治疗监控中的研究进展[J]. 临床泌尿外科杂志, 2023, 38(11): 880-885.
[6] Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications[J]. J Hematol Oncol, 2022, 15(1): 131. doi: 10.1186/s13045-022-01351-y
[7] Deng ZC, Wu SM, Wang YL, et al. Circulating tumor cell isolation for cancer diagnosis and prognosis[J]. EBioMedicine, 2022, 83: 104237. doi: 10.1016/j.ebiom.2022.104237
[8] Ashworth TR. A case of cancer in which cells similar to those in the tumor were seen in the blood after death[J]. Aust Med J, 1869, 14: 146.
[9] Ring A, Nguyen-Sträuli BD, Wicki A, et al. Biology, vulnerabilities and clinical applications of circulating tumour cells[J]. Nat Rev Cancer, 2023, 23(2): 95-111. doi: 10.1038/s41568-022-00536-4
[10] Abouleila Y, Onidani K, Ali A, et al. Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells[J]. Cancer Sci, 2019, 110(2): 697-706. doi: 10.1111/cas.13915
[11] Liu X, Li JJ, Cadilha BL, et al. Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis[J]. Sci Adv, 2019, 5(6): eaav4275. doi: 10.1126/sciadv.aav4275
[12] Park J, Chang ES, Kim JY, et al. C-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer[J]. Breast Cancer Res, 2024, 26(1): 13. doi: 10.1186/s13058-024-01768-y
[13] Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology[J]. Genes Dev, 2017, 31(18): 1827-1840. doi: 10.1101/gad.305805.117
[14] Wu SY, Liu SY, Liu ZM, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers[J]. PLoS One, 2015, 10(4): e0123976. doi: 10.1371/journal.pone.0123976
[15] Guan XW, Ma F, Li CX, et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer[J]. Cancer Commun, 2019, 39(1): 1.
[16] Shen ZY, Wu AG, Chen XY. Current detection technologies for circulating tumor cells[J]. Chem Soc Rev, 2017, 46(8): 2038-2056. doi: 10.1039/C6CS00803H
[17] Tang P, Thongrom B, Arora S, et al. Polyglycerol-based biomedical matrix for immunomagnetic circulating tumor cell isolation and their expansion into tumor spheroids for drug screening[J]. Adv Healthc Mater, 2023, 12(26): e2300842. doi: 10.1002/adhm.202300842
[18] Au SH, Edd J, Stoddard AE, et al. Microfluidic isolation of circulating tumor cell clusters by size and asymmetry[J]. Sci Rep, 2017, 7(1): 2433. doi: 10.1038/s41598-017-01150-3
[19] Yagi S, Koh Y, Akamatsu H, et al. Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients[J]. PLoS One, 2017, 12(6): e0179744. doi: 10.1371/journal.pone.0179744
[20] Zhu Y, Podolak J, Zhao R, et al. Proteome profiling of 1 to 5 spiked circulating tumor cells isolated from whole blood using immunodensity enrichment, laser capture microdissection, nanodroplet sample processing, and ultrasensitive nanoLC-MS[J]. Anal Chem, 2018, 90(20): 11756-11759. doi: 10.1021/acs.analchem.8b03268
[21] Sabath DE, Perrone ME, Clein A, et al. Clinical validation of a circulating tumor cell assay using density centrifugation and automated immunofluorescence microscopy[J]. Am J Clin Pathol, 2022, 158(2): 270-276. doi: 10.1093/ajcp/aqac040
[22] Vora N, Shekar P, Hanulia T, et al. Deep learning-enabled detection of rare circulating tumor cell clusters in whole blood using label-free, flow cytometry[J]. Lab Chip, 2024, 24(8): 2237-2252. doi: 10.1039/D3LC00694H
[23] Ruiz-Rodríguez AJ, Molina-Vallejo MP, Aznar-Peralta I, et al. Deep phenotypic characterisation of CTCs by combination of microfluidic isolation(IsoFlux)and imaging flow cytometry(ImageStream)[J]. Cancers, 2021, 13(24): 6386. doi: 10.3390/cancers13246386
[24] Li GL, Ji Y, Wu YH, et al. Multistage microfluidic cell sorting method and chip based on size and stiffness[J]. Biosens Bioelectron, 2023, 237: 115451. doi: 10.1016/j.bios.2023.115451
[25] Signorelli R, Giret TM, Umland O, et al. ALCAM: a novel surface marker on EpCAMlowcirculating tumor cells[J]. Biomedicines, 2022, 10(8): 1983. doi: 10.3390/biomedicines10081983
[26] Wu CY, Yan L, Zhan ZX, et al. Biomolecules-mediated electrochemical signals of Cu2+: Y-DNA nanomachines enable homogeneous rapid one-step assay of lung cancer circulating tumor cells[J]. Biosens Bioelectron, 2024, 249: 116030. doi: 10.1016/j.bios.2024.116030
[27] Chen LL, Zhou WP, Ye ZY, et al. Predictive value of circulating tumor cells based on subtraction enrichment for recurrence risk in stage Ⅱ colorectal cancer[J]. ACS Appl Mater Interfaces, 2022, 14(31): 35389-35399. doi: 10.1021/acsami.2c08560
[28] Zavridou M, Smilkou S, Tserpeli V, et al. Development and analytical validation of a 6-plex reverse transcription droplet digital PCR assay for the absolute quantification of prostate cancer biomarkers in circulating tumor cells of patients with metastatic castration-resistant prostate cancer[J]. Clin Chem, 2022, 68(10): 1323-1335. doi: 10.1093/clinchem/hvac125
[29] Chen JY, Xie T, Yang J, et al. Feasibility study of expressing epcam+/vimentin+CTC in prostate cancer diagnosis[J]. J Cancer Res Clin Oncol, 2023, 149(11): 8699-8709. doi: 10.1007/s00432-023-04819-7
[30] Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells[J]. Nat Rev Cancer, 2019, 19(10): 553-567. doi: 10.1038/s41568-019-0180-2
[31] Goodman CR, Seagle BL, Friedl TWP, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer[J]. JAMA Oncol, 2018, 4(8): e180163. doi: 10.1001/jamaoncol.2018.0163
[32] Cho H, Byun SS, Son NH, et al. Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in different stages of prostate cancer[J]. Clin Cancer Res, 2024, 30(9): 1788-1800. doi: 10.1158/1078-0432.CCR-23-3083
[33] Jiang SM, Wang H, Zhu JJ, et al. Identify the clinicopathological characteristics of lung carcinoma patients being false negative in folate receptor based circulating tumor cell detection[J]. Small Methods, 2023, 7(9): e2300055. doi: 10.1002/smtd.202300055
[34] Salehi M, Lavasani ZM, Keshavarz Alikhani H, et al. Circulating tumor cells as a promising tool for early detection of hepatocellular carcinoma[J]. Cells, 2023, 12(18): 2260. doi: 10.3390/cells12182260
[35] Zhang Z, Fan W, Deng QL, et al. The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies[J]. Oncotarget, 2017, 8(35): 59527-59538. doi: 10.18632/oncotarget.18521
[36] Nicolazzo C, Busetto GM, Gradilone A, et al. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial[J]. Oncologist, 2019, 24(5): 612-616. doi: 10.1634/theoncologist.2018-0784
[37] Jin D, Qian L, Xia J, et al. In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer[J]. Med Oncol, 2023, 40(4): 113. doi: 10.1007/s12032-023-01977-z
[38] Fu GH, Cheng KS, Chen AQ, et al. Microfluidic assaying of circulating tumor cells and its application in risk stratification of urothelial bladder cancer[J]. Front Oncol, 2021, 11: 701298. doi: 10.3389/fonc.2021.701298
[39] 刘杰, 孙宇鹏, 李小航, 等. 尿路上皮癌患者外周血循环肿瘤细胞检测及其与临床特征和预后的关系[J]. 现代肿瘤医学, 2022, 30(19): 3551-3555. doi: 10.3969/j.issn.1672-4992.2022.19.021
[40] Bergmann S, Coym A, Ott L, et al. Evaluation of PD-L1 expression on circulating tumor cells(CTCs)in patients with advanced urothelial carcinoma(UC)[J]. Oncoimmunology, 2020, 9(1): 1738798. doi: 10.1080/2162402X.2020.1738798
[41] Yang X, Lv JC, Zhou ZJ, et al. Clinical application of circulating tumor cells and circulating endothelial cells in predicting bladder cancer prognosis and neoadjuvant chemosensitivity[J]. Front Oncol, 2021, 11: 802188.
[42] Jin D, Qian L, Xia J, et al. In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy[J]. Cell Oncol, 2023, 46(3): 793-797. doi: 10.1007/s13402-023-00785-x
[43] Busetto GM, Ferro M, del Giudice F, et al. The prognostic role of circulating tumor cells(CTC)in high-risk non-muscle-invasive bladder cancer[J]. Clin Genitourin Cancer, 2017, 15(4): e661-e666. doi: 10.1016/j.clgc.2017.01.011
[44] Jiang H, Gu XJ, Zuo ZH, et al. Prognostic value of circulating tumor cells in patients with bladder cancer: a meta-analysis[J]. PLoS One, 2021, 16(7): e0254433. doi: 10.1371/journal.pone.0254433
[45] Liu J, Ma CL, Li XH, et al. Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients[J]. Int Urol Nephrol, 2023, 55(2): 309-318.
[46] 钟蛟, 刘浩然, 汪道琦, 等. 外周血循环肿瘤细胞的表型及TOP2A表达与膀胱癌复发转移及预后的关系[J]. 现代泌尿生殖肿瘤杂志, 2021, 13(5): 268-273. doi: 10.3870/j.issn.1674-4624.2021.05.004
[47] Carrasco R, Ingelmo-Torres M, Gómez A, et al. Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer[J]. World J Urol, 2022, 40(8): 2033-2039. doi: 10.1007/s00345-022-04061-9
-
计量
- 文章访问数: 96
- 施引文献: 0
下载: